Reducing Lead Dust Exposure in Older Housing

Reducing Lead Dust Exposure and Childhood Blood Lead Levels in Older Housing in Michigan

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07485608

Enrollment

Registered

2026-03-20

Start date

2022-12-01

Completion date

2026-11-30

Last updated

2026-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elevated Blood Lead Levels, Exposure to Toxic Dust

Brief summary

The objective of this study is to assess the effectiveness of portable air filtration (PAF) for mitigating lead dust exposures and reducing childhood blood lead levels in older housing.

Detailed description

In close collaboration with local health departments, this project will enroll 40 participants who (1) reside in housing built before 1970, and (2) have children under six years of age with blood lead levels (BLL) \>5 μg/dL. Specific objectives include (1) assess reduction of Pb dust exposure via the intervention, (2) assess the ability of PAF to reduce childhood BLL indirectly via reductions in Pb dust exposure, and (3) develop evidence-based exposure reduction guidance for wider public use of PAF. The project team will measure Pb levels in (1) suspended dust, (2) floor dust, and (3) children's blood before the start and finish of the two-month-long intervention as well as at the midpoint.

Interventions

OTHERportable air filtration systems

Two portable air filtration units placed in subjects' homes (one in child's bedroom and one in living room) will be kept running for two months.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

No minimum to 7 Years

Healthy volunteers

Inclusion criteria

* child under seven years of age with BLL \>5 µg/dL, * child must reside in housing built before 1978, and * child must sleep at home during participation in the two month-long study.

Exclusion criteria

* anything in child's health history that could affect the study results, or * any circumstance that could interfere with guardian's/parent's ability to consent and/or participate in the study.

Design outcomes

Primary

Measure	Time frame	Description
Change in blood lead level	After two months at the end of the intervention	change in blood lead level (in ug/dL).

Countries

United States

Contacts

CONTACTTuan Nguyen, BS

nguye620@msu.edu517-884-2043

CONTACTMasako Morishita, PhD

tomoko@msu.edu517-884-0463

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 21, 2026